Category Archives: Stem Cell Clinic

Allogene allies with Notch to make CAR-T production more scalable –

Last year, Arie Belldegrun and David Chang, fresh from selling chimeric antigen receptor (CAR)-T pioneer Kite Pharma to Gilead Sciences, launched Allogene with $300m (271m) and a deal with Pfizer to access off-the-shelf cell therapies. The focus then, as now, was on taking CAR-T therapies mainstream by eliminating factors that could restrict them to niche status, such as the complex, costly production process.

Allogenes founding allogeneic technology moves it some way toward that goal, by enabling therapies to be made from donor cells rather than having to engineer cells taken from the patient themselves.

However, even if the allogeneic approach works as Allogene hopes, it will still require a steady supply of donor cells. When Allogene launched, it set its sights on making up to 100 doses from one donor sample.

The finite nature of donated T cells has spurred interest in induced pluripotent stem cells (iPSC), which could serve as a renewable source of materials for off-the-shelf CAR-T therapies. Notchs work to realize that potential caught the attention of Allogenes CEO, David Chang.

Chang said, We believe [it] to be a scalable and potentially more [good manufacturing practice] amenable manufacturing process. It might be amenable for large-scale manufacturing.

The early stage nature of the iPSC technology Notch is yet to enter the clinic means it is unclear whether the approach can live up to those expectations. An inability to show CAR-T doses are free from undifferentiated iPSCs and failure to generate functioning T cells from iPSCs are two potential stumbling blocks.

Allogene has seen enough potential to bet on Notch, though. The deal will see Allogene pay Notch $10m upfront, take a 25% stake in its new partner and commit to a package of milestones.

Notch will take iPSC AlloCAR T cells through preclinical development before Allogene steps in to test them in humans. Allogene will have global rights to any products resulting from the collaboration.

Other companies are also working to develop oncology cell therapies based on iPSCs. Fate Therapeutics is trialling an engineered natural killer cell therapy created from a clonal master iPSC line, while Bayer-backed startup Century Therapeutics recently raised $250m to take iPSC-derived treatments for blood cancers and solid tumors into the clinic. Takeda is also active in the space.

Continue reading here:
Allogene allies with Notch to make CAR-T production more scalable -

Stem cell Manufacturing Market: is predicted to reach a valuation of by 2027 – Weekly Spy

Global Stem cell manufacturing Industry Analysis of the value chain helps to analyze major raw materials, major equipment, production processes, customer analysis and major Stem cell manufacturing Market distributors. A comprehensive analysis of the statistics, market share, performance of the company, historical analysis Till 2018, volume, revenue, growth rate of YOY and CAGR forecast for 2027 is included in the report. Research Report also provides explicit information in recent years on mergers, acquisitions, joint ventures and other important market activities. Research Analysis report also provides Porter analysis, PESTEL analysis and market attractiveness to better understand the macro-and micro-level market scenario. Stem cell manufacturing report also includes a detailed description, a competitive scenario, a wide range of market leaders and business strategies adopted by competitors with their analysis of SWOT.

Get the inside scope of the Sample report @


Stem cell manufacturing discusses the required technologies that enable the transfer of the current laboratory-based practice of stem cell tissue culture to the clinic environment as therapeutics, while concurrently achieving control, reproducibility, automation, validation, and safety of the process and the product.

The market of stem cell manufacturing is anticipated to grow with a significant rate in the coming years, owing to the factors such as, growing public-private investments and funding in stem cell-based research, rising public awareness regarding the therapeutic potency of stem cell products, development of advanced genomic analysis techniques for quality control during stem cell manufacturing, technological advancements in stem cell manufacturing and preservation, and evolving regulatory frameworks for stem cell therapeutics.

The report also includes the profiles of key stem cell manufacturing companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years. Some of the key players influencing the market are Merck KGaA, Thermo Fisher Scientific, Inc., BD, Bio-Rad Laboratories, Inc., Miltenyi Biotec, Pharmicell Co., Ltd, Takara Bio Inc., STEMCELL Technologies Inc., Osiris Therapeutics, Inc., and NuVasive, Inc. among others.

Market size & shares

Market trends and dynamics

Market Drivers and Opportunities

Competitive landscape

Supply and demand

Technological inventions in industry

Marketing Channel Development Trend

Market Positioning

Pricing Strategy

Brand Strategy

Target Client


The Global Stem cell manufacturing Market Analysis to 2027 is a specialized and in-depth study of the biotechnology industry with a focus on the global market trend. The report aims to provide an overview of global stem cell manufacturing market with detailed market segmentation by of product, application and end user. The global stem cell manufacturing market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the market. On the other hand, increasing market focus on embryonic stem cells and induced pluripotent stem cells are expected to offer new growth platforms to conduct advanced research and developments for the players in the global stem cell manufacturing market.

Market segmentation:

Stem Cell Manufacturing Market to 2027 Global Analysis and Forecasts By Product (Stem Cell Lines, Instruments, Culture Media, And Consumables) Application (Research Applications, Clinical Applications, and Cell and Tissue Banking) End User (Pharmaceutical and Biotechnology Companies, Hospitals and Surgical Centers, Academic Institutes, Research Laboratories, and Cros, Cell Banks, and Tissue Banks) and Geography

By Geography North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. And 13 countries globally along with current trend and opportunities prevailing in the region.

The target audience for the report on the market


Market analysts

Senior executives

Business development managers


R&D staff




Equity research firms


Click to buy full report with all description:-

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Read the rest here:
Stem cell Manufacturing Market: is predicted to reach a valuation of by 2027 - Weekly Spy

Vertex invests in gene therapy manufacturing –

Across 2019, Vertex has struck deals intended to yield a new generation of breakthrough medicines.

In June, Vertex agreed to pay $245m (220m) upfront to acquire Exonics Therapeutics for its gene editing technology and pipeline of programs targeting diseases including Duchenne muscular dystrophy (DMD). Months later, Vertex put up another $950m to buy Semma Therapeutics and its cell therapy treatment for type I diabetes.

The acquisitions moved Vertex, which started out in small molecules, into new areas, and building out capabilities in those areas will cost money.

In recent years, Vertex has grown its annual operating expenses by 10% to 14%. Talking on a recent quarterly results conference call, Vertex CFO Charles Wagner warned investors to expect costs to rise faster in 2020.

Wagner said, Our current expectation is that the rate of growth will be somewhat higher in 2020 as we invest in research and preclinical manufacturing for selling genetic therapies in support of our programs in type I diabetes, DMD and other diseases.

The move into type I diabetes also takes Vertex into territory that, to some observers, looks different than the areas the company has targeted historically.

Asked by an analyst about the shift in focus, Vertex CEO Jeff Leiden downplayed the differences, noting that type I diabetes is treated in the US in a relatively small number ofcenters that can be targeted by a speciality sales force.

Researchers have achieved positive, long-term outcomes by transplanting cadaveric islets into patients but two barriers have stopped companies from industrialising that approach.

Firstly, there are too few cadaveric islets to treat all type I diabetics. Secondly, immunosuppression is needed to stop patients from rejecting the transplanted cells.

Semma is trying to tackle the problems by differentiating stem cells and using a device to protect them from the immune system. Vertex thinks these technologies are the breakthroughs the field needs to industrialize the concept.

Leiden said, We were watching companies who are addressing those two problems for the last two, three years. And over the last six to eight months, we were convinced that Semma has actually solved both of those problems.

Vertex reached that conclusion on the strength of preclinical data. Now, Vertex is set to invest to find out whether the idea works in the clinic.

Read the original:
Vertex invests in gene therapy manufacturing -

[Weekly Funding Roundup] Startups raised $53.3M, a drop of 75.8 pc from last week – YourStory

This week, startups raised $53.3 million in equity funding, down 75.8 percent as compared to last week's $220.7 million. Three venture debt deals were also signed that saw startups raising a total of $6.1 million.

Weekly Funding Roundup

PayU co-founder Jitendra Guptas latest venture, Digifin raised $24 million in an early-stage round from Matrix Partners, Sequoia Capital, Greyhound Capital, 3One4 Capital, Rocket Internet, BeeNext, and Tanglin Venture Partners. The company operates under Amica Financial Technologies.

Exam preparation startup Gradeup this week said it had received $7 million in Series A funding from Times Internet. This is the second fundraise for Gradeup, taking the total funds raised by the startup to $10 million. Gradeup will use the funds to enhance its technology and product capabilities, diversify offerings, and scale its academic team.

Online learning platform Adda247 raised Series B funding of $6 million led by Infoedge (India) Ltd and Asha Impact. STL, a current investor of Adda247, also participated in the latest round. With this round, Adda247 has raised a total of $10 million of funds to date.

Delhi-based healthcare platform BeYouPlus raised$3.2 millionin its Series A funding round, led byIvyCap Ventures.The round also saw participation fromMadison CapitalandSingapore Angel Network, among others.

SafeHouse Technologies, that focusses on mobile-first cybersecurity, raised $2.2 million in a seed funding round led by Barclays UK Ventures, the venture capital business unit of British multinational financial services group Barclays.

Residential proptech startup YourOwnROOM raised $1.3 million in seed fundingfrom a group of investors that includes US-based investment firm Lotus Capital; Ravi Chaturvedi, former President of P&G; Narasimha Murthy, Co-founder of a US-based healthtech company; and a group of angel investors based out of the USand Bengaluru.

Bengaluru-based transport service for kids, PiggyRide raised $1.05 million (Rs 7.5 crore) led by JAFCO Investment Asia Pacific, along with a clutch of angel investors, including InMobis Naveen Tewari; Livspace Co-founders Ramakant Sharma and Anuj Srivastava; Goldman Sachs' MD, Niladri Mukhopadhyay; Zipdials Amiya Pathak; and EzCreds Sachin Maheshwari.

Pet-care platform Wiggles raised angel funding of $1 million from investors such asNachikhet Deshpande, COO of L&T Infotech; Aparna Badkundri, Director, Dell Computers; Sachin Phadke, MD of Vetbiochem India; Abhay Amrute, Senior Partner, IIFL Wealth Management Ltd; Satish Billakota, VP, Europe Cognizant; Risshee Tandulwadkar, Founder, Solo Stem Cell Clinic, apart from a few other HNIs.

Mumbai-based edtech startup ENpower, which provides entrepreneurship learning programmes for teenagers, raised seed funding of $0.37 million (Rs 2.65 crore) from an investor consortium led by Nikhil Vora, Founder & CEO of Sixth Sense Ventures, a consumer-centric venture fund.

The Knotty Tales, a tech startup that acts as a digital wedding planning platform, raised $0.06 million from a group of angel investors as a part of its seed round. This fundraising will be used to focus on new product innovation and further strengthening relationships with clients and vendors.

Seed investor Venture Catalysts invested an undisclosed amount in deep-tech computer vision and augmented reality (AR) specific startup peAR Technologies.

Mitrata Financial Services, a women-focussed microlender, raised Series A funding from a group of individual investors. Sadaf Sayeed, CEO of Muthoot Microfin, was one of the investors in Mitrata.

Mumbai-based podcast startup Kuku FM raised an undisclosed amount from the dream team of VCs 3one4 Capital, Shunwei Capital (a Chinese investment firm spun off from handset-maker Xiaomi), and India Quotient. This investment has raised the bar for the Kuku FM team. The funds raised will be used to expand its content library and increase its user base.

Vehicle maintenance startup Hoopy raised an undisclosed amount of funding from Lead Angels and Venture Farmer. Bengaluru-based family office Venture Farmer typically makes Pre-Series A to Series B investments ranging between $100k-$700k.

Delhi-based startup goStops, a premium chain of youth traveller hostels, raised an undisclosed amount of funds in its initial funding round from angel investors.

Corefactors, an integrated sales and marketing company, raised an undisclosed amount in its seed round from Mumbai based angel investment firm, Ah! Ventures.

There was one late-stage deal this week. Omnichannel furniture brand Urban Ladder has raised close to $2.1 million (Rs 14.91 crore) from SAIF Partners, Steadview Capital and Sequoia Capital India, as a follow-on of its Series E round, according to regulatory filings accessed by YourStory.

News and classifieds platform Lokal raised $3 million from 3one4 Capital, Y Combinator, RB Investments, SOMA Capital, and its existing investor India Quotient. Focused on regional languages, Lokal will be using the freshly raised funds to improve its product and expand to newer geographies.

Data, analytics, and decisioning company Experian has picked up a strategic stake in smart data mobile marketing platform Vserv Digital Services. While the deal size and amount were undisclosed, the company stated the investment was in line with its vision to boost financial inclusion, by ensuring a friction-free digital onboarding experience for its consumers.

Hyderabad-based Thinkwide PGO raised $1 million in equity funding from Sreeni Musani of Ektha Pvt. Ltd. and Narsi Reddy Posham of IRA Reality Pvt. Ltd. The startup has also received an additional commitment of $1 million in equity investment from the same set of investors.

Online furniture rental firm Furlenco raised Rs 2.5 crore ($1.6 million) debt funding from Sandeep Baid, Shakuntalam Holdings, and Ritona Vincom.The company has issued 250 non-convertible debentures (NCDs) of face value Rs 1 lakh each for the same.

Consumer and small and medium enterprises (SMEs) focussed digital lending app InCred raised Rs 31.4 crore ($4.4 million) in its second round of debt financing.

Furniture and electronics leasing platform, Rentomojo raised Rs 1 crore ($0.14 million) as non-convertible debentures (NCDs) from Kamal Bhandari on private placement basis.

Used vehicle marketplace Droom acquired NBFC Xeraphin Finvest Pvt. Ltd.

SoftBank-backed robotic process automation (RPA) player Automation Anywhere which acqui-hired engineering startup Cathyos Labs.

And finally, Netcore Solutions acquiredAI startup

(Edited by Suman Singh and Saheli Sen Gupta)

Original post:
[Weekly Funding Roundup] Startups raised $53.3M, a drop of 75.8 pc from last week - YourStory

Pet Care Startup Wiggles Raises $1 Mn, Will Expand Its Footprint – Inc42 Media

Wiggles provides pet-focused products across India via partnerships with ecommerce companies

With funds, Wiggles will strengthen its presence, distribution and expand its product range

Wiggles has witnessed 40% month on month growth since June 2019

Pune-based pet healthcare and wellness startup, Wiggles, on Thursday, has raised $1 Mn funding in its first funding round from a long list of angel investors, investing in their own personal capacity.

Among the angel investors, prominent ones included Nachikhet Deshpande, COO of L&T Infotech, Aparna Badkundri, director, Dell Computers, Dr Sachin Phadke, managing director of Vetbiochem India, Abhay Amrute, senior partner, IIFL Wealth Management Ltd, Satish Billakota, vice president, Europe Cognizant, and Rishi Tanduulwadkar, founder of Solo Stem Cell Clinic, among others.

Founded in 2018 by father-daughter duo of Anushka Iyer and Rajh V Iyer along with Venky Mahadevan, Wiggles provides pet-focused products across India via partnerships with ecommerce companies.

Besides selling its products online, Wiggles also provides vet on call and grooming services across Pune and Mumbai.

With its first round of funds, Wiggles will strengthen its presence, operations, distribution and expand its product range and introduce more products. Additionally, the company is also planning to increase its footprint and launch its services in Hyderabad and Udaipur.

Founder and CEO of Wiggles, Anushka Iyer said that the company has witnessed 40% month on month growth since June 2019 along with a 4x return on costs. Having started off our operations in a single city Pune, we have now expanded our presence to Mumbai. We are focused on creating a brand with PAN India presence, she added.

Moreover, in a press statement, the company said that it aims to introduce transparency associated with costs, medication, nutrition and wellness options across the pet industry.

Wiggles claims that the platforms flagship offering is the Wiggles Box which contains anti-parasitic medicines, nutritional products and essential vitamins for a pet, which is backed by personalised alerts through the companys app ensuring that the pets never misses their doses again.

Pet care technology has been gaining ground across the world and one dog walking startups, Wag, backed by SoftBank, has even managed to enter the unicorn league.

In India, the technology trend is picking up force with tech players operating in the pet industry. While, pet food is the major segment in India, capturing more than two-thirds of the market revenues, pet accessories, grooming and healthcare are also growing rapidly into urban markets.

Besides gaining market popularity, startups operating in this space have also been able to attract investors and bag a substantial amount of funding.

Last month, a Delhi-based pet care and products retailer, Heads Up For Tails, completed a $10 Mn Pre-Series A funding round. The investment was led by a group of family offices, HNIs and existing promoters.

Another pet care startup CoZo, in August 2019, was in talks with marquee investors Sequoia Capital and Matrix Partners for raising funds for its pet wellness service.

Pet Care Startup Wiggles Raises $1 Mn, Will Expand Its Footprint - Inc42 Media

New NCCN Guidelines Debut to Manage Complications and Improve Readiness for Stem Cell Transplant Recipients – Yahoo Finance

National Comprehensive Cancer Network expands resources to meet growing utilization of cell-based cancer treatments

PLYMOUTH MEETING, Pa., Oct. 30, 2019 /PRNewswire/ --Today, the National Comprehensive Cancer Network (NCCN ) published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) for Hematopoietic Cell Transplantation (HCT), also known as stem cell transplant or historically as bone marrow transplant. This new resource provides step-by-step information on best practices in evaluating patients for hematopoietic cell transplantation and managing complications afterwards. This type of specialized treatment is increasingly common, occurring approximately 22,000 times a year in the United States in people with various malignancies, most commonly for blood-related cancers.1

NCCN Logo (C)NCCN(R) 2018. All rights reserved.

"Establishing NCCN Guidelines for Hematopoietic Cell Transplantation is a key accomplishment in the management of blood cancers," said Ayman A. Saad, MD, Professor of Clinical Medicine, The Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute, Chair of the NCCN Guidelines Panel for HCT. "The current version of the guidelines addresses both pre-transplant evaluation and the management of a common complication: graft versus host disease (GVHD). Given the diversity of practice and expertise, we believe these guidelines will provide a pivotal tool for learning about the continuously updated therapy landscape in HCT. We hope this will help streamline clinical practices and educate new generations of physicians-in-training."

The guidelines provide recommendations on how to evaluate a potential transplant recipient to determine if the patient is an appropriate candidate for the procedure, and how to best manage different manifestations of post-transplant GVHD. They reflect the latest evidence and consensus from foremost experts across the 28 leading academic cancer centers that comprise NCCN, including hematologists/oncologists, transplant-specific practitioners, and infectious disease specialists.

"These guidelines provide an algorithmic pathway for a systematic approach to allogeneic (donor) transplantation across several different cancer types including leukemia, lymphoma, and multiple myeloma," explained Marcos de Lima, MD, Professor of Medicine, Case Comprehensive Cancer Center and University Hospitals of Cleveland , Vice-Chair of the NCCN Guidelines Panel for HCT. "Thankfully, the number of blood and bone marrow donors has increased substantially in just the past decade. When you combine the National Marrow Donor Program registry adult donors with cord blood donors and relatives (matched and mismatched), we are now able to perform this potentially cancer-curing procedure on significantly more patients than we could in the past. That's why it's so important to set standards for preventing and treating common adverse events and infections."

"Early referral for consideration of HCT can be life-saving, so we strongly encourage all oncologists to take a look at these guidelines and refer any possible candidates to transplant centers for evaluation," said Alison W. Loren, MD, MSCE, Director, Blood & Marrow Transplant, Cell Therapy & Transplant Program, Abramson Cancer Center of the University of Pennsylvania , Member of the NCCN Guidelines Panel for HCT. "We also urge oncologists who may be caring for patients after HCT to familiarize themselves with the varied manifestations of GVHDa very common and significant post-transplant complicationand to consult with transplant providers to optimize their ongoing care. The guidelines explain how to diagnose and treat this condition in order to achieve the best possible outcomes."

Story continues

The NCCN Guidelines for Hematopoietic Cell Transplantation are available free-of-charge for non-commercial use at and via the recently improved Virtual Library of NCCN Guidelines App for smartphone and tablet. NCCN will continue expanding blood cancer resources through continuous updates to the HCT guidelines, along with upcoming new NCCN Guidelines for Histiocytosis, Myeloid/Lymphoid Neoplasms, Pediatric B-Cell Lymphomas, and Pediatric Hodgkin Lymphoma.

About the National Comprehensive Cancer NetworkThe National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world.

The NCCN Member Institutions are: Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA; Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope National Medical Center, Duarte, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; O'Neal Comprehensive Cancer Center at UAB, Birmingham, AL; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Rogel Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit Patients and caregivers, visit Media, visit Follow NCCN on Twitter @NCCN, Facebook @NCCNorg, and Instagram @NCCNorg.

1 D'Souza A, Fretham C. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides. 2018. Available at:

Media Contact: Rachel Darwin 267-622-6624

View original content to download multimedia:

SOURCE National Comprehensive Cancer Network

View post:
New NCCN Guidelines Debut to Manage Complications and Improve Readiness for Stem Cell Transplant Recipients - Yahoo Finance

Stem Cell Research and Hair Transplants How Far Have We Come? – Science Times

(Photo : Stem cell research and hair transplants how far have we come?)

We all know that hair loss is a major problem, particularly for men around the world. While men who have enough hair left can have hair transplant procedures such as the FUT, FUE or DHI, done, this is not always possible.

It is always a smart move to consult with a hair loss specialist regardless of your situation because they may still be able to suggest something if you still have some hair. Only the specialist can tell assess what your situation is and what options are available. You can, for example, always contact a specialist at the Vera Clinic in Turkey to get evaluated.

In fact, men who are already very bald and have lost most of the hair found in the donor areas such as the back of the head may be out of luck when it comes to being able to have transplant surgery. This is a reason that scientists have been conducting experiments using stem cells. Some types of stem cells can be used to regenerate other types of cells and tissues in the body, so it is only natural that the idea came about to use stem cells to grow new hair follicles.

Stem cell research

There is often a lot of controversy regarding stem cell research because many people, including politicians, think that only human fetuses have stem cells and thus they argue that it is an unethical area of research. However, everybody has stem cells, not just fetuses, and it is a person's own stem cells that hold the potential to make new tissues. This is also partly why PRP therapy has been so successful, because the plasma actually contains many stem cells which trigger growth and repair of tissues.

Researchers have been able to grow some human hair follicles in the laboratory using stem cells. These same hairs were then transplanted into a mouse. Human testing cannot begin until animal testing is completed and many countries have rigorous processes in place when it comes to scientific investigations in humans.

This means that we can expect it to be some time yet before any human trials can take place using stem cells and hair transplants from follicles that are grown in the lab. The other problem which the scientists have noted is that it is more complicated than it seems since even though hair was transplanted into the mice, the outcome was not good and the hair was found to grow at odd angles. This could have been because it was a transplant between different species, but the reality is that hair transplantation is not as simple as it seem.

Stem cells may, however, be the last chance for people who have lost most of their hair. Scientists think that autologous hair transplants based on growing hair from a person's own stem cells may be something that becomes a reality in the future. At the moment, more studies need to be undertaken and the best advice is to seek treatment for hair loss before it reaches a point where nothing can be done.

Visit link:
Stem Cell Research and Hair Transplants How Far Have We Come? - Science Times

Animal Stem Cell Therapy Market Sales Overview, Market Size, Opportunities, Demands, Market Share and Growth Analysis 2017 2025 – Health News Office

The analysis and research team at TMR enables customization of report for any market study. Our experienced research analysts will understand your exact business requirement and provide the most pertinent report for competitive gains.


The market intelligence report from TMR is a valuable tool that enables vendors to identify growth avenues, and strategize for launch of products and services. These findings help businesses pave way in a crowded business landscape, and make way into the future with confidence.

To provide this, analysts carried out a succinct analysis of demand drivers, restraints, opportunities, and threats that are likely to influence the Narcotic Analgesic Combination Drugs market over the Narcotic Analgesic Combination Drugs forecast period. These market indicators serve valuable for market stakeholders for business planning, scope of expansion, financial modeling, investment proposition, and to understand competitive dynamics in the Narcotic Analgesic Combination Drugs market over the forecast period.

Request Sample Report @

The market research report on Narcotic Analgesic Combination Drugs also offers valuable insights into key business strategies employed by established players, along with impact of these strategies on future business landscape.

Market segments and sub-segments

The regional analysis covers:

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and narcotic analgesic combination drugs market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

The study is a source of reliable data on:

Request For Discount On This Report @

The regional analysis covers:

The analysis of a market presented in our reports provides valuable insights for strategic planning for businesses to obtain competitive advantage. Included in our research reports are valuable projections to understand market share that key players might hold in the future.

The report includes SWOT analysis of key players, which shall be a crucial market intelligence for mergers, acquisitions, collaborations, or partnerships between market stakeholders. In addition, the report carries out robust groundwork for inclusion of market segmentation by type, application, and geography. This helps market stakeholders gauge the best bet to make investments in the Narcotic Analgesic Combination Drugs market over the Narcotic Analgesic Combination Drugs forecast period.

Highlights of the report:

RequestTOC For ThisReport @

Key Questions Answered in the Narcotic Analgesic Combination Drugs Report

View post:
Animal Stem Cell Therapy Market Sales Overview, Market Size, Opportunities, Demands, Market Share and Growth Analysis 2017 2025 - Health News Office

Acorn Biolabs partners with Executive Health Centre to become first clinic in North America to offer non-invasive stem cell collection – Canada…

TORONTO, Oct. 23, 2019 /CNW/ -Acorn Biolabs, a pioneer in non-invasive stem cell collection, today announced a strategic partnership with Toronto-based Executive Health Centre, a medical wellness centre and leader in precision and personalized medicine. Under the agreement, Executive Health Centre will become the first clinic in North America to offer its patients the ability to have their stem cells banked through a method that involves simply plucking a few hair follicles from a person's head.

Acorn's innovative method allows for full genome collection without the need for surgery or other painful and invasive procedures, making stem cell collection significantly more affordable and accessible for everyone.

"Our partnership with Acorn is tremendously exciting for the future of healthcare," says Dr. Elaine Chin, founder of Executive Health Centre. "Stem cells play a critical role in predictive analytics and will allow us to identify and prevent diseases before they happen, in addition to creating the possibility for an array of personalized regenerative treatments in the future."

Once stem cells are collected, Acorn uses a proprietary method of keeping cells viable during transport and storage, turning collected hair follicles into a highly valuable and accessible resource for regenerative medicine and genetics. Not only are these stem cells securely stored for future use, but the company's scientists can also extract critical genetic information that will unlock valuable data about a person's health that has never been available before.With this partnership, Executive Health Centre patients will also have access to Acorn's genetic age reports that provide insights into a person's aging process.

"Dr. Chin has been a trailblazer in using biometric and monitoring technology with her patients, and has established herself as an eminent thought leader in this space. For Acorn to combine our technology with her clinic's expertise is a major win not just for patients, but also for the broader industry as a whole," says Dr. Drew Taylor, co-founder and CEO of Acorn. "Both Executive Health Centre and Acorn strongly believe that our cells are the future of healthcare, and we're thrilled to be working together in making regenerative medicine accessible to more and more people."

Media AvailabilityTime: 4:00 p.m.Location: Executive Health Centre, 4120 Yonge Street, Toronto, ONDr. Drew Taylor and Dr. Elaine Chin are available for interviews.

About Acorn Biolabs, Inc.Founded in 2017 by Steven ten Holder, Patrick Pumputis and Dr. Drew Taylor and borne out of years of research, Acorn is a healthcare technology company. Based at Johnson & Johnson INNOVATION JLABS in Toronto, Acorn is focused on giving every human being the best chance to experience more healthy years with its easy, affordable and non-invasive live-cell collection, analysis and cryopreservation service. Acorn helps you live a longer, healthier tomorrow by freezing the clock on your cells today.Visit

About Executive Health CentreThe Executive Health Centre is recognized for its visionary work in personalized, preventative healthcare. Dr. Elaine Chin, founder of the Executive Health Centre, established North America's first physician and naturopathic doctor-integrated health clinic in 1997 at the Mississauga Hospital (now Trillium Health Partners). Today, the combined expertise of this innovative model is unmatched in North America and provides its patients the best in seamless integrative medicine and rejuvenation therapies. Dr. Chin is also the author of "Lifelines Unlocking the Secrets of Your Telomeres for a Longer, Healthier Life," on The Globe and Mail's Top 10 Bestseller List. Visit:

SOURCE Acorn Biolabs

For further information: Morgan McLellan, E:, C: 647-802-4825

More here:
Acorn Biolabs partners with Executive Health Centre to become first clinic in North America to offer non-invasive stem cell collection - Canada...

Brooks Koepka slips on wet concrete, withdraws from CJ Cup – Golfweek

World No. 1 Brooks Koepka has withdrawn from the CJ Cup.

Koepka released a statement in which he says that he slipped and aggravated an injury on his left knee.

The full statement, released on the PGA Tours twitter account, reads:

During the course of Fridays round, I slipped on wet concrete aggravating a previous injury to my left knee. After consulting with my doctor, I have been advised to withdraw from the CJ Cup and head home for further tests. I appreciate everyones concerns and support. Ill keep you posted as I learn more.

CJ CUP:Scores|Photos |Updates

A little more than two weeks ago, ahead of his season debut in the Shriners Hospitals for Children Open at TPC Summerlin in Las Vegas, Koepka revealed that he had undergone a stem cell procedure for a partially torn patella tendon. He did it to relieve discomfort and strengthen a left knee that had been bugging him since March.

The procedure was performed Sept. 2 in Orlando.

Its stem cell, so they go in and inject it into my knee, Koepka said. Im watching it on the screen, as they were doing it, and it was probably one of the most painful things, I was screaming when they did it.

The 29-year-old limped out of the clinic and stayed off his feet best he could for three days, then started rehabbing the area.

Koepka shot 69-75 over the first two rounds this week in Korea, which had him at even par, T-51 in the no-cut, 78-man field.

See original here:
Brooks Koepka slips on wet concrete, withdraws from CJ Cup - Golfweek